Orion Corporation
https://www.orion.fi/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Orion Corporation
Keeping Track: Enhertu, Nubeqa Grow With RTOR; Interchangeable Cimerli And Another Nuplazid CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Deal Watch: Cidara Licenses US Rights To Antifungal Under FDA Review To Melinta
Cidara gets $30m up front for US rights to the weekly echinocandin candidate for candidemia and invasive candidiasis. Takeda walks away from oncolytic virus candidate licensed from Turnstone.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast version of Five Must-Know Things: setback for a COVID-19 candidate; Chinese biotechs move into mRNA; Sanofi’s strategic moves into hemophilia; Orion’s deal for its novel prostate cancer candidate; and Roche’s evolving approach to platform deals.
Orion Bags Another Big Pharma Partner With Merck & Co Prostate Cancer Deal
The Finnish group has concluded an extensive search to partner its first-in-class CYP11A1 inhibitor, banking an impressive $290m upfront fee for the Phase II drug which is being evaluated for metastatic castration-resistant prostate cancer.
Company Information
- Industry
- Biotechnology
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Vaccines
-
Drug Delivery
- Pulmonary
- Other Names / Subsidiaries
-
- Orion Corporation
- Orion Diagnostica Oy
- Orion Pharma
- Orion Oyj